AccuraGen Holdings
Menlo Park
About AccuraGen Holdings
We have developed a high-sensitivity next-generation sequencing-based system for the the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $40.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2016)
- Website: accuragen.com
- Phone: +116506185028
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/accuragen-holdings-3048 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.